Tezepelumab did not significantly decrease moderate or severe COPD exacerbations compared with placebo, the COURSE trial found.
Explore strategies for controlling COPD and improving health, with a focus on management and lifestyle changes.
Among patients with COPD who experienced an exacerbation, the risk for cardiovascular events was highest in the following 2 weeks and stayed elevated more than 1 year after, according to study results ...
Amarillo Globe-News on MSN7d
What are Zephyr Valves? Groundbreaking COPD treatment brings hope to Panhandle patientsAfter waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...
Study reveals the Prospector calculator reduces antibiotic prescriptions in COPD exacerbations, improving outcomes and ...
Chronic obstructive pulmonary disease ... This article reviews the current literature related to the treatment of COPD exacerbations and examines whether these data support current treatment ...
Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback